Evaluation of physiologically based pharmacokinetic models for use in risk assessment

Journal of Applied Toxicology

Volumn 27, Issue 3, 2007, Pages 218-237

  Chiu, Weihsueh A ^a   Barton, Hugh A ^a   DeWoskin, Robert S ^b   Schlosser, Paul ^a   Thompson, Chad M ^a   Sonawane, Babasaheb ^a   Lipscomb, John C ^a   Krishnan, Kannan ^c  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Dosimetry models; Evaluation; PBPK models; Risk assessment

Indexed keywords

COMPUTER ANALYSIS; DOSIMETRY; MATHEMATICAL MODEL; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ALGORITHMS; ANIMALS; COMPUTER SIMULATION; HAZARDOUS SUBSTANCES; HUMANS; MODELS, BIOLOGICAL; MONITORING, PHYSIOLOGIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 34247510787     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1225     Document Type: Review

References (144)

1. Abraham MH, Weathersby PK. 1994. Hydrogen bonding. 30. Solubility of gases and vapors in biological liquids and tissues. J. Pharm. Sci. 83: 1450-1456.
2. Allen BC, Covington TR, Clewell HJ. 1996. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111: 289-303.
3. Andersen ME. 1995. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol. Lett. 79: 35-44.
4. Andersen ME, Birnbaum LS, Barton HA, Eklund CR. 1997. Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol. Appl. Pharmacol. 144: 145-155.
5. Andersen ME, Clewell HJ, III, Frederick CB. 1995. Applying simulation modeling to problems in toxicology and risk assessment - a short perspective. Toxicol. Appl. Pharmacol. 133: 181-187.
6. Andersen ME, Clewell HJ, III, Gargas ML, MacNaughton MG, Reitz RH, Nolan RJ, McKenna MJ. 1991. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol. Appl. Pharmacol. 108: 14-27.
7. Andersen ME, Clewell HJ, III, Gargas ML, Smith FA, Reitz RH. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87: 185-205.
8. Andersen ME, Gargas ML, Jones RA, Jenkins LJ, Jr. 1980. Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. Toxicol. Appl. Pharmacol. 54: 100-116.
9. Arms AD, Travis CC. 1998. Reference physiological parameters in pharmacokinetic modeling. EPA/600/6-88/004. U.S. Environmental Protection Agency, Office of Health and Environmental Assessment: Washington, DC.
10. Astrand P, Rodahl K. 1970. Texbook of work physiology. McGraw Hill: New York.
11. Balci O. Verification, validation, and accreditation of simulation models. In Proceedings of the 1997 Winter Simulation Conference, December 7-10, 1997, Andradottir S, Healy KJ, Withers DH, Nelson BL (eds). pp. 135-141.
12. Ball R, Schwartz SL. 1994. CMATRIX: software for physiologically based pharmacokinetic modeling using a symbolic matrix representation system. Comput. Biol. Med. 24: 269-276.
13. Beliveau M, Lipscomb J, Tardif R, Krishnan K. 2005. Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. Chem. Res. Toxicol. 18: 475-485.
14. Beliveau M, Tardif R, Krishnan K. 2003. Quantitative structure-property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats. Toxicol. Appl. Pharmacol. 189: 221-232.
15. Bernillon P, Bois FY. 2000. Statistical issues in toxicokinetic modeling: a bayesian perspective. Environ. Health Perspect. 108(Suppl 5): 883-893.
16. Blancato JN, Saleh AM. 1994. Physiologically based pharmacokinetic models. Examples of their use in exposure and risk assessment. In Biomarkers of Human Exposure to Pesticides, Saleh AM, Blancato JN, Nauman CH (eds). American Chemistry Society: Washington, DC; 264-283.
17. Bogaards JJ, Freidig AP, van Bladeren PJ. 2001. Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling. Chem. Biol. Interact. 138: 247-265.
18. Bois FY. 1999. Analysis of PBPK models for risk characterization. Ann. N. Y. Acad. Sci. 895: 317-337.
19. Bois FY. 2000a. Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108(Suppl 2): 275-282.
20. Bois FY. 2000b. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108(Suppl 2): 307-316.
21. Bois FY, Woodruff TJ, Spear RC. 1991. Comparison of three physiologically based pharmacokinetic models of benzene disposition. Toxicol. Appl. Pharmacol. 110: 79-88.
22. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13: 407-484.
23. Burmaster DE, Murray DM. 1998. A trivariate distribution for the height, weight, and fat of adult men. Risk Anal. 18: 385-389.
24. Chen HS, Gross JF. 1979. Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models. J. Pharmacokinet. Biopharm. 7: 117-125.
25. Chiu WA, Bois FY. 2006. Revisiting the population toxicokinetics of tetrachloroethylene. Arch. Toxicol 80: 382-385.
26. Chiu WA, White P. 2006. Steady-state solutions to PBPK models and their applications to risk assessment I: route-to-route extrapolation of volatile chemicals. Risk Anal. 26: 1-12.
27. Clark LH, Setzer RW, Barton HA. 2004. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 24: 1697-1717.
28. Clewell HJ, III, Andersen ME. 1987. Dose, species and route extrapolation using physiologically-based pharmacokinetic models. Drink Water and Health 8: 159-182.
29. Clewell HJ, III, Andersen ME. 1996. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111: 315-329.
30. Clewell HJ, III, Lee TS, Carpenter RL. 1994. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal. 14: 521-531.
31. Cole CE, Tran HT, Schlosser PM. 2001. Physiologically based pharmacokinetic modeling of benzene metabolism in mice through extrapolation from in vitro to in vivo. J. Toxicol. Environ. Health A 62: 439-465.
32. Collins AS, Sumner SC, Borghoff SJ, Medinsky MA. 1999. A physiological model for tert-amyl methyl ether and tert-amyl alcohol: hypothesis testing of model structures. Toxicol. Sci. 49: 15-28.
33. Corley RA, Mast TJ, Carney EW, Rogers JM, Daston GP. 2003. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit. Rev. Toxicol. 33: 137-211.
34. Dankovic DA, Bailer AJ. 1994. The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. Fundam. Appl. Toxicol. 22: 20-25.
35. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10: 1093-1095.
36. Dong MH. 1994. Microcomputer programs for physiologically-based pharmacokinetic (PB-PK) modelling. Comput. Methods Programs Biomed. 45: 213-221.
37. Easterling MR, Evans MV, Kenyon EM. 2000. Comparative analysis of software for physiologically based pharmacokinetic modeling: simulation, optimization, and sensitivity analysis. Toxicol. Methods 10: 203-229.
38. Edler L. 1999. Uncertainty in biomonitoring and kinetic modeling. Ann. N. Y. Acad. Sci. 895: 80-100.
39. el-Masri HA, Bell DA, Portier CJ. 1999. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol. Appl. Pharmacol. 158: 221-230.
40. Evans MV, Andersen ME. 2000. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol. Sci. 54: 71-80.
41. Farrar D, Allen B, Crump K, Shipp A. 1989. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. Toxicol. Lett. 49: 371-385.
42. Filser JG, Bolt HM. 1979. Pharmacokinetics of halogenated ethylenes in rats. Arch. Toxicol. 42: 123-136.
43. Filser JG, Bolt HM. 1981. Inhalation pharmacokinetics based on gas uptake studies. I. Improvement of kinetic models. Arch. Toxicol. 47: 279-292.
44. Fiserova-Bergerova V. 1995. Extrapolation of physiological parameters for physiologically based simulation models. Toxicol. Lett. 79: 77-86.
45. Fisher J, Mahle D, Bankston L, Greene R, Gearhart J. 1997. Lactational transfer of volatile chemicals in breast milk. Am. Ind. Hyg. Assoc. J. 58: 425-431.
46. Gabrielsson J, Bondesson U. 1987. Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. J. Pharmacokinet. Biopharm. 15: 583-599.
47. Gallo JM, Lam FC, Perrier DG. 1987. Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J. Pharmacokinet. Biopharm. 15: 271-280.
48. Gargas ML, Andersen ME, Clewell HJ, III. 1986. A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86: 341-352.
49. Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen ME. 1989. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98: 87-99.
50. Gelman A, Bois F, Jiang J. 1996. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91: 436.
51. Gentry PR, Covington TR, Andersen ME, Clewell HJ, III. 2002. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul. Toxicol. Pharmacol. 36: 51-68.
52. Gentry PR, Covington TR, Clewell HJ, III. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul. Toxicol. Pharmacol. 38: 1-16.
53. Gentry PR, Haber LT, McDonald TB, Zhao Q, Covington T, Nance P, Clewell HJ, III, Lipscomb JC, Barton HA. 2004. Data for physiologically based pharmacokinetic modeling in neonatal animals: physiological parameters in mice and Sprague-Dawley rats. J. Children's Health 2: 363-411.
54. Gerlowski LE and Jain RJ. 1983. Physiologically based pharmacokine-tic modeling: principles and applications. J Pharm Sci 72: 1103-27.
55. Gueorguieva I, Nestorov IA, Rowland M. 2006. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J Pharmacokinet Pharmacodyn. 33: 1-27.
56. Haber LT, Maier A, Gentry PR, Clewell HJ, Dourson ML. 2002. Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Toxicol. Pharmacol. 35: 177-197.
57. Haddad S, Gad SC, Tardif R, Krishnan K. 1995. Statistical approaches for the evaluation of physiologically-based pharmacokinetic (PBPK) models. Abstract. Toxicologist. 15: 48.
58. Haddad S, Pelekis M, Krishnan K. 1996. A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol. Lett. 85: 113-126.
59. Haddad S, Restieri C, Krishnan K. 2001. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health A 64: 453-464.
60. Haddad S, Tardif R, Withey J, Krishnan K. 1997. Rate of pyrene metabolism in rat liver post-mitochondrial fractions. Toxicol. Lett. 93: 177-184.
61. Haddad S, Withey JR, Lapare S, Law F, Krishnan K. 1998. Physiologically based pharmacokinetic modeling of pyrene in the rat. Environ. Toxicol. Pharmacol. 5: 245-255.
62. Hattis D, Ginsberg G, Sonawane B, Smolenski S, Russ A, Kozlak M, Goble R. 2003. Differences in pharmacokinetics between children and adults - II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal. 23: 117-142.
63. Hattis D, White P, Marmorstein L, Koch P. 1990. Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors. Risk Anal. 10: 449-458.
64. Hetrick DM, Jarabek AM, Travis CC. 1991. Sensitivity analysis for physiologically based pharmacokinetic models. J. Pharmacokinet. Biopharm. 19: 1-20.
65. Himmelstein KJ, Lutz RJ. 1979. A review of the application of physiologically based pharmacokinetic modeling. J. Pharm. Biopharm. 7: 127-145.
66. Hissink EM, Bogaards JJP, Freidig AP, Commandeur JNM, Vermeulen NPE, van Bladeren PJ. 2002. The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene. Environ. Toxicol. Pharmacol. 11: 259-271.
67. Hoang, KCT. 1995. Physiologically based pharmacokinetic models-mathematical fundamentals and simulation implementations. Toxicol Lett. 79: 87-98.
68. Holmes SL, Ward RC, Galambos JD, Strickler DJ. 2000. A method for optimization of pharmacokinetic models. Toxicol. Methods 10: 41-53.
69. ICRP (International Commission on Radiological Protection). 1975. Report of the Task Group on Reference Man. Pergamon Press: New York, NY.
70. Igari Y, Sugiyama Y, Sawada Y, Iga T, Hanano M. 1983. Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model. J. Pharmacokinet. Biopharm. 11: 577-593.
71. Isukapalli SS, Roy A, Georgopoulos PG. 1998. Stochastic response surface methods (SRSMs) for uncertainty propagation: application to environmental and biological systems. Risk Anal. 18: 351-363.
72. Jepson GW, Hoover DK, Black RK, McCafferty JD, Mahle DA, Gearhart JM. 1994. A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundam. Appl. Toxicol. 22: 519-524.
73. Johanson G, Jonsson F, Bois F. 1999. Development of new technique for risk assessment using physiologically based toxicokinetic models. Am. J. Ind. Med. (Suppl 1): 101-103.
74. Johanson G, Naslund PH. 1988. Spreadsheet programming: a new approach in physiologically based modeling of solvent toxicokinetics. Toxicol Lett 41: 115-127.
75. Jonsson F, Johanson G. 2001. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 157: 177-193.
76. Jonsson F, Johanson G. 2002. Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach. Toxicol. Appl. Pharmacol. 179: 35-49.
77. Jonsson F, Johanson G. 2003. The Bayesian population approach to physiological toxicokinetic-toxicodynamic models - an example using the MCSim software. Toxicol Lett 138: 143-150.
78. Karba R, Zupancic B, Bremsak F. 1990. Simulation tools in pharmacokinetic modelling. Acta Pharm Jugosl 40: 247-262.
79. Kedderis GL, Held SD. 1996. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 140: 124-130.
80. Kedderis GL, Lipscomb JC. 2001. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment. Toxicol. Ind. Health 17: 315-321.
81. Keys DA, Bruckner JV, Muralidhara S, Fisher JW. 2003. Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene. Toxicol. Sci. 76: 35-50.
82. Kohn MC. 1995. Achieving credibility in risk assessment models. Toxicol Lett. 79: 107-114.
83. Krewski D, Wang Y, Bartlett S, Krishnan K. 1995. Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. J. Biopharm. Stat. 5: 245-271.
84. Krishnan K, Andersen M. Physiologically based pharmacokinetic models in the risk assessment of developmental neurotoxins. In Handbook of Developmental Neurotoxicology, Slikker W (ed.). Academic Press: New York; 709-725.
85. Krishnan K, Andersen ME. Physiologically based pharmacokinetic modeling in toxicology. In Principles and Methods of Toxicology, Hayes K (ed.). Taylor & Francis: Philadelphia; 193-241.
86. Krishnan K, Gargas ML, Fennell TR, Andersen ME. 1992. A physiologically based description of ethylene oxide dosimetry in the rat. Toxicol. Ind. Health 8: 121-140.
87. Lam G, Chen ML, Chiou WL. 1982. Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. J. Pharm. Sci. 71: 454-456.
88. Leggett RW, Williams LR. 1991. Suggested reference values for regional blood flow in humans. Health Phys. 60: 139-154.
89. Leung HW. 1991. Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J. Toxicol. Environ. Health 32: 247-267.
90. Lilly PD, Andersen ME, Ross TM, Pegram RA. 1998. A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat. Toxicol. Appl. Pharmacol. 150: 205-217.
91. Lin JH, Sugiyama Y, Awazu S, Hanano M. 1982. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J. Pharmacokinet. Biopharm. 10: 637-647.
92. Lipscomb JC, Barton HA, Tornero-Velez R, Evans MV, Alcasey S, Snawder JE, Laskey J. 2004. The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J. Toxicol. Environ. Health A 67: 537-553.
93. Lipscomb JC, Fisher JW, Confer PD, Byczkowski JZ. 1998. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol. Appl. Pharmacol. 152: 376-387.
94. Lipscomb JC, Kedderis GL. 2002. Incorporating human interindividual biotransformation variance in health risk assessment. Sci. Total Environ. 288: 13-21.
95. Lipscomb JC, Teuschler LK, Swartout J, Popken D, Cox T, Kedderis GL. 2003. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23: 1221-1238.
96. Luecke RH, Wosilait WD, Pearce BA, Young JF. 1994. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49: 90-103.
97. Mattie DR, Bates GD, Jr, Jepson GW, Fisher JW, McDougal JN. 1994. Determination of skin:air partition coefficients for volatile chemicals: experimental method and applications. Fundam. Appl. Toxicol. 22: 51-57.
98. Mendez J, Keys A. 1960. Density and composition of mammalian muscle. Metabolism 9: 184-188.
99. Menzel DB, Wolpert RL, Boger JR, Kootsey JM. 1987. Resources available for simulation in toxicology: specialized computers, generalized software and communication networks. Drink Water and Health 8: 229-254.
100. Mortensen B, Lokken T, Zahlsen K, Nilsen OG. 1997. Comparison and in vivo relevance of two different in vitro head space metabolic systems: liver S9 and liver slices. Pharmacol. Toxicol. 81: 35-41.
101. Mortensen B, Nilsen OG. 1998. Allometric species comparison of toluene and n-hexane metabolism: prediction of hepatic clearance in man from experiments with rodent liver S9 in a head space vial equilibration system. Pharmacol. Toxicol. 82: 183-188.
102. Murphy JE, Janszen DB, Gargas ML. 1995. An in vitro method for determination of tissue partition coefficients of non-volatile chemicals such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and estradiol. J. Appl. Toxicol. 15: 147-152.
103. Nestorov I. 2001. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol. Lett. 120: 411-420.
104. Nichols J, Rheingans P, Lothenbach D, McGeachie R, Swoi L, McJim J. 1994. Three-dimensional visualization of physiologically based kinetic model outputs. Environ. Health Perspect. 102: 952-956.
105. Nong A, McCarver DG, Hines RN, Krishnan K. 2006. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 214: 78-87.
106. OECD (Organisation for Economic Co-operation and Development). 2004. Report from the group on quantitative structure-activity relationships: on the principles for the validation of QSARs. OECD, Paris, Nov 2004.
107. Payne MP, Kenny LC. 2002. Comparison of models for the estimation of biological partition coefficients. J. Toxicol. Environ. Health A 65: 897-931.
108. Pelekis M, Nicolich MJ, Gauthier JS. 2003. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors. Risk Anal. 23: 1239-1255.
109. Ploemen JP, Wormhoudt LW, Haenen GR, Oudshoorn MJ, Commandeur JN, Vermeulen NP, de W, I, Beaune PH, Watabe T, van Bladeren PJ. 1997. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. Toxicol. Appl. Pharmacol. 143: 56-69.
110. Portier CJ, Kaplan NL. 1989. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. Fundam. Appl. Toxicol. 13: 533-544.
111. Poulin P, Krishnan K. 1995. A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals. Hum. Exp. Toxicol. 14: 273-280.
112. Poulin P, Krishnan K. 1996a. A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol. Appl. Pharmacol. 136: 131-137.
113. Poulin P, Krishnan K. 1996b. A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Toxicol. Appl. Pharmacol. 136: 126-130.
114. Poulin P, Theil FP. 2000. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89: 16-35.
115. Price K, Haddad S, Krishnan K. 2003a. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A 66: 417-433.
116. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, Tedder DR. 2003b. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev. Toxicol. 33: 469-503.
117. Ramsey JC, Andersen ME. 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73: 159-175.
118. Reddy MB, Andersen ME, Morrow PE, Dobrev ID, Varaprath S, Plotzke KP, Utell MJ. 2003. Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. Toxicol. Sci. 72: 3-18.
119. Reitz RH, Gargas ML, Andersen ME, Provan WM, Green TL. 1996a. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol. Appl. Pharmacol. 137: 253-267:
120. Reitz RH, Gargas ML, Mendrala AL, Schumann AM. 1996b. In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans. Toxicol. Appl. Pharmacol. 136: 289-306.
121. Reitz RH, Mendrala AL, Guengerich FP. 1989. In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. Toxicol. Appl. Pharmacol. 97: 230-246.
122. Rey TD, Havranek WA. 1996. Some aspects of using the SimuSolv program for environmental, pharmacokinetics and toxicological applications. Ecol Model 86: 277-282.
123. Ross R, Leger L, Guardo R, de GJ, Pike BG. 1991. Adipose tissue volume measured by magnetic resonance imaging and computerized tomography in rats. J. Appl. Physiol 70: 2164-2172.
124. Rowland M. 1985. Physiologic pharmacokinetic models and interanimal species scaling. Pharmacol. Ther. 29: 49-68.
125. Sarangapani R, Gentry PR, Covington TR, Teeguarden JG, Clewell HJ, III. 2003. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 15: 987-1016.
126. Sato A, Endoh K, Kaneko T, Johanson G. 1991. A simulation study of physiological factors affecting pharmacokinetic behaviour of organic solvent vapours. Br. J. Ind. Med. 48: 342-347.
127. Sato A, Nakajima T. 1979. Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br. J. Ind. Med. 36: 231-234.
128. Schoeffner DJ, Warren DA, Muralidara S, Bruckner JV, Simmons JE. 1999. Organ weights and fat volume in rats as a function of strain and age. J. Toxicol. Environ. Health A 56: 449-462.
129. Simmons JE, Boyes WK, Bushnell PJ, Raymer JH, Limsakun T, McDonald A, Sey YM, Evans MV. 2002. A physiologically based pharmacokinetic model for trichloroethylene in the male long-evans rat. Toxicol. Sci. 69: 3-15.
130. Sultatos LG, Kim B, Woods L. 1990. Evaluation of estimations in vitro of tissue/blood distribution coefficients for organothiophosphate insecticides. Toxicol. Appl. Pharmacol. 103: 52-55.
131. Tardif R, Charest-Tardif G, Brodeur J, Krishnan K. 1997. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol. Appl. Pharmacol. 144: 120-134.
132. Thomas RS, Lytle WE, Keefe TJ, Constan AA, Yang RS. 1996a. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method. Fundam. Appl. Toxicol. 31: 19-28.
133. Thomas RS, Yang RS, Morgan DG, Moorman MP, Kermani HR, Sloane RA, O'Connor RW, Adkins B, Jr, Gargas ML, Andersen ME. 1996b. PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure. Environ. Health Perspect. 104: 858-865.
134. Thrall KD, Vucelick ME, Gies RA, Zangar RC, Weitz KK, Poet TS, Springer DL, Grant DM, Benson JM. 2000. Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling. J. Toxicol. Environ. Health A 60: 531-548.
135. Timchalk C, Nolan RJ, Mendrala AL, Dittenber DA, Brzak KA, Mattsson JL. 2002. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 66: 34-53.
136. U.S. Department of Health and Human Services (U.S. DHHS). 1999. Guidance for industry. Population pharmacokinetics. Food and Drug Administration, Center for Drug Evaluation and research, Center for Biologics Evaluation and Research, 31pp.
137. U.S.EPA. 1997. Guiding principles for Monte Carlo analysis. EPA/630/R-97/001. Risk Assessment Forum, Washington, DC.
138. U.S.EPA. 2006a. Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment. EPA/600/R-05/043F. National Center for Environmental Assessment: Washington, DC.
139. U.S.EPA. 2006b. Use of physiologically based pharmacokinetic models to quantify the impact of human age and interindividual differences in physiology and biochemistry pertinent to risk. EPA/600/R-06/014A. National Center for Environmental Assessment: Cincinnati, OH.
140. Valentin J. 2002. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Annals of the ICRP 32: 1-277.
141. Vicini P, Pierce CH, Dills RL, Morgan MS, Kalman DA. 1999. Individual prior information in a physiological model of 2H8-toluene kinetics: an empirical Bayes estimation strategy. Risk Anal. 19: 1127-1134.
142. West JB, Wagner PD. 1991. Ventilation-perfusion relationships. In The Lung: Scientific Foundations, Crystal RG, West JB (eds). Raven Press: New York; 1289-1305.
143. Wünscher G, Kersting H, Heberer H, Westmeier I, Wenzel V, Flechsig M, Mattaeus E. 1991. Simulation system SONCHES-based toxicokinetic model and data bank as a tool in biological monitoring and risk assessment. Sci Total Environ 101: 101-109.
144. Yates FE. 1978. Good manners in good modeling: mathematical models and computer simulations of physiological systems. Am. J. Physiol 234: R159-R160.